ClinicalTrials.gg
RecruitingNCT05098769Updated Mar 11, 2026

A Predictive Tool for Predicting Adverse Outcomes in Acute Pulmonary Embolism Patients Using CTPA.

An observational study in Pulmonary Embolism and Thrombosis and Deterioration, Clinical, sponsored by Shengjing Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-11.

Sponsored by Shengjing Hospital · Observational

How we know

From the registry’s dates

  • Started Jan 2021; still recruiting 5 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
300
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 72 studies in Pulmonary Embolism with a site in China — 26 open to participants now, 31 under way, 1 of them phase 3. Pulmonary Embolism · China.

Planned enrollment
30th of 39
300 · median 1,000
Started
2021
with 1 other
Observational
39 of 72
20 open now
Primary completion
2026-12
later than 14 of 30 live
Registered
37th of 72
by date
Lead sponsor
3 of 72
Shengjing Hospital

Among the 72 studies in Pulmonary Embolism with a site in China, this one is the 30th largest by planned enrollment of the 39 observational ones that give a count, is one of 2 that started in 2021, is one of 39 observational ones, reaches primary completion later than 14 of the 30 other live ones, and was the 37th registered.

Pulmonary Embolism

833 studies on the registry are indexed under Pulmonary Embolism; 172 are open to participants now.

Browse Pulmonary Embolism studies →

Open to participants now

26 of the 72 studies in Pulmonary Embolism with a site in China are open now. Recruiting first, the newest first:

20 more — sign in →

All 26 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 130 Pulmonary Embolism studies recruiting now, 110 (85%) set no upper age limit and 5 (4%) stop at 75 or younger; 9 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 72 studies in Pulmonary Embolism with a site in China, or all of them as a file.
02

Study summary

This study collected clinical, laboratory, and CT parameters of acute patients with acute pulmonary embolism from admission to predict adverse outcomes within 30 days after admission into hospital.

Read the detailed description

This study collected clinical, laboratory, and CT parameters of acute patients with acute pulmonary embolism from admission. The outcomes of interest were defined as the occurrence of adverse outcomes within 30 days after admission into hospital.

Eligible patients were randomized in some ratio into derivation and validation cohorts. The derivation cohort was used to develop and evaluate a multivariable logistic regression model for predicting the outcomes of interest. The discriminatory power was evaluated by comparing the nomogram to the established risk stratification systems. The consistency of the nomogram was evaluated using the validation cohort.

03

Conditions studied

  • Pulmonary Embolism and Thrombosis
  • Deterioration, Clinical

Keywords

  • Pulmonary Embolism and Thrombosis
  • Deterioration, Clinical
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Chinese

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age of ≥ 18 years and a PE diagnosis based on CT pulmonary angiography

Exclusion criteria

Exclusion Criteria:

  • pregnancy
  • reception of reperfusion treatment before admission
  • missing data regarding CT parameters, echocardiography, cardiac troponin I (c-Tn I), and N-terminal-pro brain natriuretic peptide (NT-pro BNP) levels.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
300 participants (estimated)
Target follow-up
30 Days
Patient registry
Yes

Groups and cohorts

  • Acute pulmonary embolism

    an age of ≥ 18 years and a PE diagnosis based on CT pulmonary angiography

06

What researchers measure

Primary outcomes

  1. Adverse outcomes

    The outcomes of interest were defined as the occurrence of adverse outcomes within 30 days after admission. Adverse outcomes were defined as PE-related deaths, the need for mechanical ventilation, the need for cardiopulmonary resuscitation, and the need for life-saving vasopressor and reperfusion treatment.

    Time frame: 7 days and 30 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Gao Y, Gu Z, Wei X, Wei S, Liu Y, Zhan S, Yang J, Qi C, Qi S, Wang M, Jia D. Ventricular septum curvature ratio: a novel imaging marker to predict clinical deterioration in normotensive acute pulmonary embolism. Crit Care. 2025 Oct 31;29(1):463. doi: 10.1186/s13054-025-05708-w. PubMed 41174707 ↗
  • Gao Y, Wei S, Liu Y, Yu Z, Zhan S, Yang B, Qi C, Qi S, Wang M, Jia D. Predicting Deterioration in Patients With Normotensive Acute Pulmonary Embolism Using Clinical-Imaging Features: A Multicenter Prospective Cohort Study. J Am Heart Assoc. 2025 Jul;14(13):e038984. doi: 10.1161/JAHA.124.038984. Epub 2025 Jun 27. PubMed 40576035 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2021 (actual). Primary completion is estimated for Dec 2026, 71 months after the start.

Of 135 non-industry observational studies under Pulmonary Embolism, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 119. This study's planned 71 months is above that.

Counting every sponsor, half of 160 studies reached it within 47 months; a quarter within 21 and three quarters within 105.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2021
First posted
Oct 28, 2021
StartActual
Jan 18, 2021
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Mar 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05098769
Lead sponsor
Shengjing Hospital
Responsible party
YIZHUO GAO (Principal Investigator, Shengjing Hospital) — Principal investigator
First posted
Oct 28, 2021
Start date
Jan 18, 2021
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Mar 11, 2026

Study contacts

YIZHUO GAO
Contact
gaoyizhuo.sy@hotmail.com
+86-18940257523

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion